Parexel International Corp., a Waltham biotechnology services company, said it has purchased software maker Liquent Inc. for $72 million. Liquent makes software used by drug companies to manage regulatory submissions and product registration. The deal will allow Parexel to expand the consulting services it provides to biotech and medical device companies. Parexel helps biotechs bring their drugs to market and helps to maximize sales after drugs become available.
Parexel acquires software maker for $72m
You have reached the limit of 10 free articles in a month
Stay informed with unlimited access to Boston’s trusted news source.
- High-quality journalism from the region’s largest newsroom
- Convenient access across all of your devices
- Today’s Headlines daily newsletter
- Subscriber-only access to exclusive offers, events, contests, eBooks, and more
- Less than 25¢ a week